Start with the scopeAuthorization and labelled-use references mainly describe the United States. Changing country does not verify local approval, supply or delivery. Investigational compounds, compounded products and approved medicines are distinguished. No clinician review is claimed.
Showing 8 guides; references are linked for each connection.
Evidence & quality guide2026-10-17
Peptides are amino-acid chains; the boundary with small proteins is a matter of terminology. A molecular category is not a treatment indication, and an injectable presentation does not itself prove a substance is a peptide or a useful medicine.
- Route / discussion scope
- Route is product-specific; injection is not a wellness benefit
- Conditions / goals discussed
- Medicine and injection safety
Approved peptide medicinesDefined conditions / product-specific labels
Clinical use belongs to an exact medicine and indication.
Approval of one product does not approve an entire molecular category. Source ↗
Compounded injectable productsQuality and evidence assessment
A preparation must be evaluated on its own evidence and quality controls.
Compounding is not the same as FDA premarket approval. Source ↗
Health goals & wellness limitsUseful goals include metabolic care, fracture prevention and management of diagnosed hormone disorders. General claims such as detox, immunity boosting or longevity need their own clinical evidence. A legal supply pathway does not establish those benefits.
Read the full guide & references →U.S. labelled-use references2026-10-17
Semaglutide is a peptide GLP-1 receptor agonist. It influences glucose regulation and appetite. The ingredient exists in different products, including injectable and oral formulations; their indications and instructions are not interchangeable.
- Route / discussion scope
- Subcutaneous injection; oral products also exist
- Conditions / goals discussed
- Type 2 diabetes · Obesity
SemaglutideType 2 diabetes / glucose control
Supports glucose-dependent insulin release.
An obesity-branded product is not an automatic substitute. Source ↗
SemaglutideObesity / selected overweight patients
Appetite effects support medically supervised weight management.
Eligibility is product- and patient-specific. Source ↗
Health goals & wellness limitsWeight treatment is structured medical care with nutrition, activity and follow-up. A weight-loss indication does not establish rejuvenation or longevity benefits in healthy people. Compounded products do not inherit FDA approval from a branded ingredient. [C2,C3]
Read the full guide & references →U.S. labelled-use references2026-10-17
Tirzepatide is a peptide that acts at GIP and GLP-1 receptors. Its metabolic actions connect diabetes, body weight and selected obesity-related conditions; this does not make it a universal health tonic.
- Route / discussion scope
- Subcutaneous injection
- Conditions / goals discussed
- Type 2 diabetes · Obesity · Obstructive sleep apnoea
TirzepatideType 2 diabetes
Acts through incretin pathways to help glucose regulation.
Match the product to the diabetes indication. Source ↗
TirzepatideChronic weight management
Reduces appetite and food intake.
Use within a wider medical care plan. Source ↗
Tirzepatide / ZepboundOSA with obesity: specific U.S. indication
Weight-related effects can improve this defined sleep-apnoea population.
Not a general replacement for sleep-apnoea assessment or devices. Source ↗
Health goals & wellness limitsMetabolic improvement is not proof of general anti-ageing benefit. Track the diagnosed condition and functional goals rather than using a lower weight as the sole definition of health. [C3]
Read the full guide & references →U.S. labelled-use references2026-10-17
Insulin medicines replace or supplement the action of a peptide hormone. Preparations differ in onset and duration. Human insulin and insulin analogues form a family of medicines rather than one interchangeable injection.
- Route / discussion scope
- Usually subcutaneous; some preparations have supervised intravenous uses
- Conditions / goals discussed
- Type 1 diabetes · Type 2 diabetes
Insulin medicinesType 1 diabetes / hormone replacement
Provide insulin activity that is missing.
Requires individual training and monitoring. Source ↗
Insulin medicinesType 2 diabetes / selected treatment plans
Supplement insulin when the treatment plan requires it.
Low glucose remains a major safety concern. Source ↗
Health goals & wellness limitsAn anabolic mechanism is not evidence that nonmedical insulin use is a safe muscle-building or anti-ageing practice. The appropriate health-management connection is diabetes education and prevention of hypoglycaemia. [C2]
Read the full guide & references →U.S. labelled-use references2026-10-17
Teriparatide is a fragment of parathyroid hormone used as a bone-forming medicine. Its medical purpose is distinct from nutrition products marketed for general bone health.
- Route / discussion scope
- Subcutaneous injection
- Conditions / goals discussed
- Osteoporosis
TeriparatideOsteoporosis / selected high-fracture-risk patients
Stimulates bone formation through PTH-related signalling.
Eligibility depends on the individual bone and medical history. Source ↗
Health goals & wellness limitsBone health also involves activity, fall prevention and nutritional assessment. Those goals do not turn a prescription hormone fragment into a general anti-ageing injection. [C2]
Read the full guide & references →U.S. labelled-use references2026-10-17
Octreotide is a peptide analogue of somatostatin. It can suppress several hormone signals; that pharmacology is relevant to defined disorders, not proof of general hormone balancing.
- Route / discussion scope
- Injectable formulations; route varies with the exact product
- Conditions / goals discussed
- Acromegaly · Neuroendocrine tumours
OctreotideAcromegaly / excess growth hormone
Suppresses growth-hormone release in selected patients.
Requires specialist diagnosis and follow-up. Source ↗
OctreotideSelected secretory tumour symptoms
Can control carcinoid-related flushing/diarrhoea and VIPoma-related diarrhoea.
Symptom control is not equivalent to cure. Source ↗
Health goals & wellness limitsThe useful health-management link is follow-up of the diagnosed endocrine or tumour condition. Claims of detoxification or broad anti-ageing benefit cannot be inferred from hormone suppression.
Read the full guide & references →U.S. labelled-use references2026-10-17
Desmopressin is a synthetic peptide analogue of vasopressin. It influences water handling and can affect clotting-factor release. Different routes and preparations serve different clinical purposes.
- Route / discussion scope
- Intravenous or subcutaneous for specified injection products/uses
- Conditions / goals discussed
- Central diabetes insipidus · Selected bleeding disorders
Desmopressin injectionCentral diabetes insipidus
Provides antidiuretic activity in a defined deficiency disorder.
Do not confuse with glucose-lowering treatment. Source ↗
Desmopressin injectionSelected haemophilia A / type I VWD
Can increase relevant clotting-factor availability.
Not suitable for all bleeding disorders or VWD types. Source ↗
Health goals & wellness limitsPreserving hydration and treating a water-balance disorder are different tasks. This medicine is not an everyday hydration or rejuvenation injection.
Read the full guide & references →Human evidence gaps2026-10-17
Peptide therapeutics include established medicines and compounds under investigation. Being a peptide, or acting in a cell or animal experiment, does not establish clinical benefit for an injected consumer product.
- Route / discussion scope
- Injectable claims reviewed; no administration protocol provided
- Conditions / goals discussed
- Injury recovery claims · Healthy-ageing claims
BPC-157Recovery claims / evidence gap
Proposed biological effects do not establish a clinical recovery benefit.
FDA identifies limited safety information and immunogenicity concerns. Source ↗
TB-500 / thymosin beta-4 fragmentRecovery claims / evidence gap
Research terminology does not establish an approved recovery treatment.
Identity, impurities and route-specific evidence need scrutiny. Source ↗
Injectable GHK-CuSkin/anti-ageing claims / evidence gap
Topical or mechanistic findings cannot establish injectable benefit.
Human safety data are limited for injected products. Source ↗
Health goals & wellness limitsFor injury recovery, skin health or healthy ageing, ask for human outcomes relevant to the exact claim, not mechanisms alone. This is an evidence-review topic, not a treatment recommendation or a purchasing directory.
Read the full guide & references →